


FORM PTO-1449
(Rev. 2-32)U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

Serial No.

01-034

09/760,119

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

Sarah S. Bacus

Filing Date:

01/12/2001

Group:

1642

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation
					Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

KAC	1.	Bacus et al., "Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells," Oncogene 12(12):2535-47, 1996.
	2.	Chang et al., "p21 ^{Waf1/Cip1/Sdi1} -induced growth arrest is associated with depletion of mitosis-control proteins and leads to abnormal mitosis and endoreduplication in recovering cells," Oncogene 19:2165-2170, 2000.
	3.	Kopp et al., "Transforming Growth Factor β 2 (TGF- β 2) Levels in Plasma of Patients with Metastatic Breast Cancer Treated with Tamoxifen," Cancer Research 55(20):4512-4515, 1995.
	4.	Lei et al., "The expression of suppressor gene p16, p21 and p53 in nasopharyngeal carcinoma," Lin Chuang Er Bi Yan Hou Ke Za Zhi 13(9):406-8, 1999.
	5.	Meyn et al., "Apoptosis in murine tumors treated with chemotherapy agents," Anti-Cancer Drugs 6:443-450, 1995.
	6.	Shibata et al., "Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21," Cancer Gene Therapy 8:23-35, 2001.
	7.	Timmermann et al., "Re-expression of endogenous p16 ^{ink4a} in oral squamous cell carcinoma lines by 5-aza-2'-deoxycytidine treatment induces a senescence-like state," Oncogene 17(26):3445-53, 1998.

EXAMINER /Karen A. Canella, Ph.D./

DATE CONSIDERED

07/09/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.


01-034

Serial No.

09/760,119

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)



Applicant:

Sarah S. Bacus

Filing Date:

01/12/2001

Group:

1642

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation
					Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

KAC	1.	Dannecker et al.; Induction of TGF-beta by an antiprogesterin in the human breast cancer cell line T-47D; Ann. Onc., Apr 1996; 7: 391 - 395.
KAC	2.	Gillett et al.; Cyclin-dependent kinase inhibitor p27Kip1 expression and interaction with other cell cycle-associated proteins in mammary carcinoma; J Pathol, Jan 1999; 187(2): 200-6.
KAC	3.	Smith et al.; Primary chemotherapy in breast cancer; Biomed Pharmacother, Jan 1998; 52(3): 116-21.
KAC	4.	Srivastava et al.; Growth inhibition and activation of apoptotic gene expression by human chorionic gonadotropin in human breast epithelial cells; Anticancer Res, Nov 1998; 18(6A): 4003-10.
KAC	5.	Vollmer et al.; Down-regulation of tenascin expression by antiprogesterins during terminal differentiation of rat mammary tumors; Cancer Res., Sep 1992; 52: 4642 - 4648.

EXAMINER /Karen A. Canella, Ph.D./

DATE CONSIDERED 07/09/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.